Companies Dominating the Beta Thalassemia Treatment Market
- Bluebird Bio Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Acceleron Pharma, Inc.
- Celgene Corporation
- GlaxoSmithKline plc
- Incyte Corporation
- Gamida Cell
- Kiadis Pharma
- La Jolla Pharmaceutical Company
- Vertix Pharmaceuticals Incorporated
- ApoPharma Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Beta Thalassemia Treatment Market in 2025 is assessed at USD 557.4 million.
The global market size exceeded USD 523.48 million in 2024 and is set to expand at a CAGR of around 8.1%, surpassing USD 1.44 billion revenue by 2037.
North America is likely to reach USD 475.2 million by 2037, driven by increasing presence of market players in the region and growing research and development activities for new technologies in beta-thalassemia treatment.
The major players in the market include of Celgene Corporation, GlaxoSmithKline plc, Incyte Corporation, Gamida Cell, Kiadis Pharma, La Jolla Pharmaceutical Company, Vertix Pharmaceuticals Incorporated.
